A STAND UP TO CANCER inaugural Dream Team launched in 2009 to focus on epigenetic therapy will continue with a commitment of $7.5 million from the Van Andel Research Institute.
THE ASSOCIATION OF COMMUNITY CANCER CENTERS received a charitable contribution from Bristol-Myers Squibb to develop a comprehensive program in immuno-oncology for community-based providers.
NORTHWESTERN MUTUAL, through its foundation, will fund four young investigator grants for childhood cancer research. The awards support Alex’s Lemonade Stand Foundation’s young investigator program. The addition of these four research projects results in eight total funded research projects this year, an $800,000 commitment. Each researcher receives a total grant of $100,000 over two-years. Four […]
MARY KOZIK was named senior director of development at Winship Cancer Institute of Emory University.
JAMES TULSKY received the Pathfinder in Palliative Care Award from the American Cancer Society.
DAVID MAURO was named as executive vice president and chief medical officer of Advaxis Inc.
RICHARD ZELLARS was named professor and chair of radiation oncology at the Indiana University School of Medicine, pending approval by the IU trustees. He will begin his new duties in January.
BENJAMIN NEEL was named director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center. He will begin Jan. 1, 2015.
BRAD POLLOCK was named chair of the Department of Public Health Sciences at the UC Davis School of Medicine.
The European Commission granted marketing approval for Imbruvica (ibrutinib) throughout the European Union, for relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia patients who have received at least one prior therapy, or in first line CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemotherapy.
